We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+60.47%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$834M
AUM Growth
+$209M
Cap. Flow
+$138M
Cap. Flow %
16.48%
Top 10 Hldgs %
55.44%
Holding
66
New
33
Increased
9
Reduced
2
Closed
9

Top Buys

Rank Stock Value
1
AVBP icon
ArriVent BioPharma
AVBP
+$39.2M
2
EYPT icon
EyePoint Inc
EYPT
+$27.1M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$18M
4
OCUL icon
Ocular Therapeutix
OCUL
+$17.2M
5
TNYA icon
Tenaya Therapeutics
TNYA
+$13.7M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$63.2M
2
RCUS icon
Arcus Biosciences
RCUS
+$35.7M
3
CLDX icon
Celldex Therapeutics
CLDX
+$28.1M
4
ROIV icon
Roivant Sciences
ROIV
+$28M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$5.99M

Sector Composition

Rank Sector Weight
1 Healthcare 98.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$165M 19.77%
2,806,980
– –
ALPN
2
DELISTED
Alpine Immune Sciences Inc
ALPN
$49.2M 5.9%
1,241,300
– –
DNTH icon
3
Dianthus Therapeutics
DNTH
$5.68B
$41.4M 4.96%
1,380,667
+826,667
+149% +$18M
VRNA
4
DELISTED
Verona Pharma
VRNA
$38.1M 4.57%
2,369,000
– –
DYN icon
5
Dyne Therapeutics
DYN
$4.04B
$35.3M 4.23%
1,242,945
+450,000
+57% +$10.2M
AVBP icon
6
ArriVent BioPharma
AVBP
$1.48B
$34.7M 4.16%
+1,943,836
New +$39.2M
INSM icon
7
Insmed
INSM
$23.2B
$30.9M 3.71%
1,140,000
-144,000
-11% -$4.03M
CNTA
8
DELISTED
Centessa Pharmaceuticals
CNTA
$23.3M 2.79%
2,060,100
– –
EYPT icon
9
EyePoint Inc
EYPT
$1.02B
$22.6M 2.71%
+1,093,503
New +$27.1M
OCUL icon
10
Ocular Therapeutix
OCUL
$1.86B
$22.1M 2.64%
+2,425,000
New +$17.2M
GPCR icon
11
Structure Therapeutics
GPCR
$3.49B
$21.7M 2.6%
506,604
+92,604
+22% +$3.9M
BBIO icon
12
BridgeBio Pharma
BBIO
$16.5B
$21.3M 2.56%
690,000
-16,800
-2% -$571K
DFTX
13
Definium Therapeutics
DFTX
$5.73B
$20.2M 2.43%
+2,153,000
New +$12.3M
CATX icon
14
Perspective Therapeutics
CATX
$332M
$17.5M 2.1%
+1,471,842
New +$12.6M
CRBP icon
15
Corbus Pharmaceuticals
CRBP
$170M
$15.9M 1.9%
+405,000
New +$9.99M
PRAX icon
16
Praxis Precision Medicines
PRAX
$9.07B
$15.9M 1.9%
+260,000
New +$11.7M
TNYA icon
17
Tenaya Therapeutics
TNYA
$168M
$14.9M 1.79%
+2,854,000
New +$13.7M
JSPR icon
18
Jasper Therapeutics
JSPR
$22.9M
$14.7M 1.76%
500,811
+54,000
+12% +$959K
ANNX icon
19
Annexon
ANNX
$855M
$14.7M 1.76%
2,050,000
– –
CYTK icon
20
Cytokinetics
CYTK
$11B
$13.6M 1.63%
194,000
+78,000
+67% +$6.03M
JBIO
21
Jade Biosciences
JBIO
$1.22B
$11.9M 1.43%
11,534
– –
APLS
22
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$11.8M 1.41%
+200,000
New +$12.7M
VRDN icon
23
Viridian Therapeutics
VRDN
$2.13B
$10.9M 1.3%
620,000
– –
GOSS icon
24
Gossamer Bio
GOSS
$66.5M
$10.8M 1.3%
9,187,883
– –
NAMS icon
25
NewAmsterdam Pharma
NAMS
$3.47B
$9.65M 1.16%
+408,000
New +$8.28M
1
2 3

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Octagon Capital Advisors held 66 positions worth $834M, up 34% from $625M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Octagon Capital Advisors deployed $138M of net new capital in Q1 2024, opening 33 new positions and adding to 9 existing holdings. Its largest new stake was ArriVent BioPharma: 1,943,836 shares worth $34.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $4.03M trimmed.

  • Octagon Capital Advisors's largest Q1 2024 buy was ArriVent BioPharma: 1,943,836 shares worth $34.7M.
  • Octagon Capital Advisors added most to Dianthus Therapeutics in Q1 2024, an estimated $18M increase.
  • Octagon Capital Advisors's biggest Q1 2024 reduction was Insmed, cutting an estimated $4.03M.
  • Octagon Capital Advisors fully exited Cymabay Therapeutics in Q1 2024, selling an estimated $63.2M.
  • Octagon Capital Advisors's ten largest holdings make up 55% of its $834M portfolio in Q1 2024.
  • Octagon Capital Advisors opened 33 new positions and closed 9 in Q1 2024.
  • Octagon Capital Advisors's portfolio value rose 34% quarter-over-quarter to $834M.

Based on Octagon Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.